For people with unresectable hepatocellular carcinoma, also known as advanced liver cancer that cannot be removed by surgery, finding effective treatments is a daily struggle. A new look at 270 patients across 20 centers shows that a combination of TACE, tyrosine kinase inhibitors, and immune checkpoint inhibitors might be a powerful option. This approach helped nearly half of the patients achieve a response to the treatment, and more than 60% saw their disease stop growing or shrink.
The most encouraging news is the survival data. About 52% of these patients were still alive three years after starting this triple therapy. They also lived a median of 15.9 months without the cancer getting worse before it did. These results suggest that stacking these three different types of treatment could work better than using just one or two on its own.
However, the study has some important gaps. The researchers could not say exactly which specific patients would benefit most from this complex regimen. Because the data comes from looking back at past records, we do not know if the results would hold true for everyone. Until we have more information, doctors must carefully weigh the potential benefits against the risks for each individual patient.
